Mustang Bio 11/8/2024 Earnings Report

Mustang Bio EPS Results

• Actual EPS: -$2.00
• Consensus EPS: -$6.50
• Beat/Miss: Beat by +$4.50
• One Year Ago EPS: N/A

Mustang Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Mustang Bio Announcement Details

• Date: 11/8/2024
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Mustang Bio (NASDAQ:MBIO) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas. On the rare disease front, Mustang Bio is developing gene therapy candidates aimed at lysosomal storage disorders and other inherited metabolic conditions, utilizing proprietary vector designs and manufacturing processes to deliver functional copies of deficient genes. Mustang Bio’s research collaborations and licensing agreements with leading academic institutions underpin its approach to translational science and clinical development.

Founded in 2015 and headquartered in Worcester, Massachusetts, Mustang Bio operates in North America and Europe, conducting multi‐center clinical studies to evaluate safety and efficacy of its product candidates. The company’s management team comprises industry veterans with expertise in cell therapy development, regulatory affairs and biomanufacturing. Through strategic partnerships and its own manufacturing capabilities, Mustang Bio seeks to advance first-in-class therapies from the laboratory to patients in need.